Saliva can be more effective than nasopharyngeal swabs for COVID-19 testing: Study

Washington [US], June 14 (ANI): According to a new study, the addition of a simple processing step to saliva samples before testing may improve the COVID-19 detection rate, eliminate the challenges of nasopharyngeal testing, and facilitate mass surveillance.
The findings of the study were published in the Journal of Molecular Diagnostics.
The collection of nasopharyngeal swab (NPS) samples for COVID-19 diagnostic testing poses challenges including exposure risk to healthcare workers and supply chain constraints. Saliva samples are easier to collect but can be mixed with mucus or blood, and some studies have found they produce less accurate results.
A team of researchers has found that an innovative protocol that processes saliva samples with a bead mill homogenizer before real-time PCR (RT-PCR) testing results in higher sensitivity compared to NPS samples.
"Saliva as a sample type for COVID-19 testing was a game changer in our fight against the pandemic. It helped us with increased compliance from the population for testing along with decreased exposure risk to the healthcare workers during the collection process," said lead investigator Ravindra Kolhe, MD, PhD, Department of Pathology, Medical College of Georgia, Augusta University, Augusta, GA, USA.
The study included samples from a hospital and nursing home as well as from a drive-through testing site. In the first phase (protocol U), 240 matched NPS and saliva sample pairs were tested prospectively for SARS-CoV-2 RNA by RT-PCR.
In the second phase of the study (SalivaAll), 189 matched pairs, including 85 that had been previously evaluated with protocol U, were processed in an Omni bead mill homogenizer before RT-PCR testing.
An additional study was conducted with samples with both protocol U and SalivaAll to determine if bead homogenization would affect the clinical sensitivity in NPS samples. Finally, a five-sample pooling strategy was evaluated.
Twenty positive pools containing one positive and four negative samples were processed with the Omni bead homogenizer before pooling for SARS-CoV-2 RT-PCR testing and compared to controls.
In Phase I, 28.3 per cent of samples tested positive for SARS-CoV-2 from either NPS, saliva, or both. The detection rate was lower in saliva compared to NPS (50.0 per cent vs. 89.7 per cent).
In Phase II, 50.2 per cent of samples tested positive for SARS-CoV-2 from either saliva, NPS, or both. The detection rate was higher in saliva compared to NPS samples (97.8 per cent vs. 78.9 per cent). Of the 85 saliva samples tested with both protocols, the detection rate was 100 per cent for samples tested with SalivaAll and 36.7 per cent with protocol U.
Dr Kolhe observed that the underlying issues associated with a lower sensitivity of saliva to RT-PCR testing could be attributed to the gel-like consistency of saliva samples, which made it difficult to accurately pipet samples into extraction plates for nucleic acid extraction.
Adding the homogenization step rendered the saliva samples to uniform viscosity and consistency, making it easier to pipet for the downstream assay.
Dr Kolhe and his colleagues also successfully validated saliva samples in the five-sample pooling strategy. The pooled testing results demonstrated a positive agreement of 95 percent, and the negative agreement was found to be 100 percent.
Pooled testing will be critical for SARS-CoV-2 mass surveillance as schools reopen, travel and tourism resume, and people return to offices.
"Monitoring SARS-CoV-2 will remain a public health need," Dr Kolhe said.
"The use of a non-invasive collection method and easily accessible sample such as saliva will enhance screening and surveillance activities and bypass the need for sterile swabs, expensive transport media, and exposure risk, and even the need for skilled healthcare workers for sample collection," Dr Kolhe concluded. (ANI)